Closing the evidence gap in the use of emerging testing technologies in clinical practice
- PMID: 19050197
- PMCID: PMC2910511
- DOI: 10.1001/jama.2008.754
Closing the evidence gap in the use of emerging testing technologies in clinical practice
References
-
- Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–145. - PubMed
-
- Mathews AW. Bad Cancer Tests Drawing Scrutiny. Wall Street Journal. 2008 Jan 4;:B1.
-
- Pollack A. Cancer drug may elude many women who need it. The New York Times. 2007 June 12; [Accessed on June 4, 2008]; Available at http://www.nytimes.com/2007/06/12/health/12canc.html.
-
-
Nass SJ, Moses HL, editors. Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment. Washington D.C.: The National Academies Press; 2007. Mar 27, Diagnosis, and Treatment Committee on Developing Biomarker-Based Tools for Cancer Screening; p. 252. Contract Nos. HHSH25056133, HHSN261200611002C, 200-2005-13434, HHSM-500-2005-00179P, HHSP23320042509XI, and 223-01-2460. Supported by the National Academy of Sciences and the Department of Health and Human Services; 2007.
-
-
- Stark A, Kucera G, Lu M, Claud S, Griggs J. Influence of health insurance status on inclusion of HER-2/neu testing in the diagnostic workup of breast cancer patients. Int J Qual Health Care. 2004;16(6):517–521. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous